ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1170

Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1

Jessica Bryon1, Christopher Wasson1, Rebecca Ross1, Elton Zeqiraj1 and Francesco Del Galdo2, 1University of Leeds, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

Meeting: ACR Convergence 2022

Keywords: Fibroblasts, Dermal, interferon, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Elevated Type I IFN response is present in blood and affected tissues in systemic sclerosis (SSc) and correlates with disease activity and response to therapy. It is unknown whether the tissue-specific Type I IFN activation is a consequence of the response observed in blood or rather its source. SSc fibroblasts share many cellular and molecular features with cancer-associated fibroblasts (CAF), and a wealth of evidence supports the role of CAFs in inducing Type I IFN activation in epithelial cancer cells. Here, we aim to determine if keratinocytes in SSc display Type I IFN activation and the potential role of dermal fibroblasts in the process.

Methods: Skin biopsies were obtained from healthy and SSc patients’ forearms and processed for immunohistochemistry and subculture of primary fibroblasts and keratinocytes. Human skin keratinocyte cell lines (HaCats) were stimulated with conditioned media from healthy (n=3) and SSc (n=3) fibroblasts. Exosomes were isolated from supernatants of healthy and SSc cultured patient fibroblasts using a combination of ultracentrifugation and polymer-based precipitation (Total Exosome Isolation Kit; Invitrogen). Isolated cellular exosomes were visualised and assessed by immunoblotting, electron microscopy and dynamic light scattering, and these were used to stimulate HaCats. TANK-binding kinase (TBK) was inhibited using a small molecule inhibitor (GSK8612). RT-PCR based IFN array and western blot for pSTAT1 (Tyr701) were used to assess Type I IFN activation in these cells.

Results: Consistent with previous studies we found high pSTAT1 levels in the keratinocyte layer of SSc biopsies. Primary keratinocytes isolated from SSc skin biopsies lost IFN activation after cultured in-vitro. Conditioned media from SSc patient fibroblasts triggered ISG induction: MX1 (2.7 fold, p< 0.05), CXCL10 (2.8 fold, p< 0.01) and CXCL11 (1.9 fold, p< 0.05). Media fractionation by ultracentrifugation indicated that the effect on keratinocytes was driven by pelleted micro-vesicles, suggesting a potential role for cellular exosomes. Fibroblasts from SSc patients shed cellular exosomes of similar quantities and biophysical qualities compared to healthy fibroblasts. SSc exosomes induced a 2.2 fold increase in STAT1 phosphorylation (p< 0.05) and an induction in ISGs, compared to HC exosomes: MX1 (1.45 fold, p< 0.05), CXCL10 (1.84 fold, p< 0.01), CXCL11 (2.11 fold, p< 0.01) and OAS (1.24 fold, p< 0.05). TBK inhibition by GSK8612 suppressed induction by SSc exosomes of pSTAT1 by 83%. Consistent with these findings, IFN array of HaCats stimulated with SSc exosomes showed a significant upregulation of 16 ISGs by at least 1.2 fold compared to healthy control exosomes (p< 0.05).

Conclusion: We show for the first time that scleroderma keratinocytes IFN activation observed in skin biopsies is lost in cells cultured in-vitro. We also show that fibroblast-derived exosomes can re-induce IFN activation though a TBK-dependent mechanism. Exosomes from SSc fibroblasts may carry the “signal zero” of local Type I IFN activation, potentially though nucleic acid induced activation of toll-like receptors, STING or pattern recognition receptors, such as RIG-I.


Disclosures: J. Bryon, None; C. Wasson, None; R. Ross, None; E. Zeqiraj, None; F. Del Galdo, AbbVie/Abbott, AstraZeneca, Boehringer-Ingelheim, Mitsubishi-Tanabe, Capella biosciences, Chemomab LTD, Kymab.

To cite this abstract in AMA style:

Bryon J, Wasson C, Ross R, Zeqiraj E, Del Galdo F. Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1 [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/systemic-sclerosis-dermal-fibroblast-derived-exosomes-trigger-a-type-1-interferon-rresponse-in-keratinocytes-through-tbk1/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-sclerosis-dermal-fibroblast-derived-exosomes-trigger-a-type-1-interferon-rresponse-in-keratinocytes-through-tbk1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology